Literature DB >> 15855497

Bactericidal activity of first-choice antibiotics against gamma interferon-induced persistent infection of human epithelial cells by Chlamydia trachomatis.

Nathalie Reveneau1, Deborah D Crane, Elizabeth Fischer, Harlan D Caldwell.   

Abstract

Chlamydia trachomatis is responsible for clinically important chronic inflammatory diseases of humans, including trachoma and pelvic inflammatory disease. Persistent infection of mucosal sites may contribute to the development of these chronic inflammatory diseases. Standard clinical therapy results in satisfactory cure rates of acute infections; however, chronic infection associated with persistence has been suggested to be less responsive to antibiotic therapy. We report the efficiency of two first-line chlamydial antibiotics, azithromycin and doxycycline, under conditions of eradication of C. trachomatis persistent infection using the in vitro model of gamma interferon (IFN-gamma)-mediated persistence and reactivation from persistence. Doxycycline was superior in eradicating acute (minimal bactericidal concentration [MBC](100) = 2.5 to 5.0 microg/ml) compared to persistent (MBC(100) = 10 to 50 mirog/ml) infection. In contrast, azithromycin was significantly more effective in eradicating persistent infection (MBC(100) = 2.5 to 5.0 microg/ml) than acute infection (MBC(100) = 10 to 50 microg/ml). The superior bactericidal effect of azithromycin against persistent infection was found to correlate with the enhanced uptake of the drug by IFN-gamma-treated infected epithelial cells. Based on these findings, we hypothesize that azithromycin should be a particularly efficacious anti-infective agent for the eradication of IFN-gamma-induced chlamydial persistent infection in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15855497      PMCID: PMC1087634          DOI: 10.1128/AAC.49.5.1787-1793.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

Review 1.  Immunity to murine chlamydial genital infection.

Authors:  Richard P Morrison; Harlan D Caldwell
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

2.  Transcriptome analysis of chlamydial growth during IFN-gamma-mediated persistence and reactivation.

Authors:  Robert J Belland; David E Nelson; Dezso Virok; Deborah D Crane; Daniel Hogan; Daniel Sturdevant; Wandy L Beatty; Harlan D Caldwell
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-12       Impact factor: 11.205

Review 3.  Repeated and persistent infection with Chlamydia and the development of chronic inflammation and disease.

Authors:  W L Beatty; G I Byrne; R P Morrison
Journal:  Trends Microbiol       Date:  1994-03       Impact factor: 17.079

4.  Etiology and outcome of acute pelvic inflammatory disease.

Authors:  R C Brunham; B Binns; F Guijon; D Danforth; M L Kosseim; F Rand; J McDowell; E Rayner
Journal:  J Infect Dis       Date:  1988-09       Impact factor: 5.226

5.  Nonculture methods for diagnosing chlamydial infection in patients with trachoma: a clue to the pathogenesis of the disease?

Authors:  J Schachter; J Moncada; C R Dawson; J Sheppard; P Courtright; M E Said; S Zaki; S F Hafez; A Lorincz
Journal:  J Infect Dis       Date:  1988-12       Impact factor: 5.226

6.  CD4+ T cells play a significant role in adoptive immunity to Chlamydia trachomatis infection of the mouse genital tract.

Authors:  H Su; H D Caldwell
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

7.  A double blind study of single dose azithromycin and doxycycline in the treatment of chlamydial urethritis in males.

Authors:  A Nilsen; A Halsos; A Johansen; E Hansen; E Tørud; D Moseng; G Anestad; G Størvold
Journal:  Genitourin Med       Date:  1992-10

8.  Single-dose oral azithromycin versus seven-day doxycycline in the treatment of non-gonococcal urethritis in males.

Authors:  J Lauharanta; K Saarinen; M T Mustonen; H P Happonen
Journal:  J Antimicrob Chemother       Date:  1993-06       Impact factor: 5.790

9.  A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. The Azithromycin for Chlamydial Infections Study Group.

Authors:  D H Martin; T F Mroczkowski; Z A Dalu; J McCarty; R B Jones; S J Hopkins; R B Johnson
Journal:  N Engl J Med       Date:  1992-09-24       Impact factor: 91.245

10.  Detection of Chlamydia trachomatis by enzyme immunoassay in patients with trachoma.

Authors:  D C Mabey; J N Robertson; M E Ward
Journal:  Lancet       Date:  1987-12-26       Impact factor: 79.321

View more
  20 in total

Review 1.  The case for further treatment studies of uncomplicated genital Chlamydia trachomatis infection.

Authors:  P Horner
Journal:  Sex Transm Infect       Date:  2006-08       Impact factor: 3.519

2.  Novel Detection Strategy To Rapidly Evaluate the Efficacy of Antichlamydial Agents.

Authors:  Yan Zhang; Yuqi Xian; Leiqiong Gao; Hiba Elaasar; Yao Wang; Lamiya Tauhid; Ziyu Hua; Li Shen
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

3.  Altered protein secretion of Chlamydia trachomatis in persistently infected human endocervical epithelial cells.

Authors:  Jin Wang; Kyla M Frohlich; Lyndsey Buckner; Alison J Quayle; Miao Luo; Xiaogeng Feng; Wandy Beatty; Ziyu Hua; Xiancai Rao; Maria E Lewis; Kelly Sorrells; Kerri Santiago; Guangming Zhong; Li Shen
Journal:  Microbiology (Reading)       Date:  2011-07-07       Impact factor: 2.777

4.  Inhibition of indoleamine 2,3-dioxygenase activity by levo-1-methyl tryptophan blocks gamma interferon-induced Chlamydia trachomatis persistence in human epithelial cells.

Authors:  Joyce A Ibana; Robert J Belland; Arnold H Zea; Danny J Schust; Takeshi Nagamatsu; Yasser M AbdelRahman; David J Tate; Wandy L Beatty; Ashok A Aiyar; Alison J Quayle
Journal:  Infect Immun       Date:  2011-09-12       Impact factor: 3.441

5.  Azithromycin versus Doxycycline for Urogenital Chlamydia trachomatis Infection.

Authors:  William M Geisler; Apurva Uniyal; Jeannette Y Lee; Shelly Y Lensing; Shacondra Johnson; Raymond C W Perry; Carmel M Kadrnka; Peter R Kerndt
Journal:  N Engl J Med       Date:  2015-12-24       Impact factor: 91.245

6.  Activities of first-choice antimicrobials against gamma interferon-treated Chlamydia trachomatis differ in hypoxia.

Authors:  Kensuke Shima; Matthias Klinger; Werner Solbach; Jan Rupp
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

7.  Chlamydia trachomatis infection results in a modest pro-inflammatory cytokine response and a decrease in T cell chemokine secretion in human polarized endocervical epithelial cells.

Authors:  Lyndsey R Buckner; Maria E Lewis; Sheila J Greene; Timothy P Foster; Alison J Quayle
Journal:  Cytokine       Date:  2013-05-11       Impact factor: 3.861

8.  Induction of the Chlamydia muridarum stress/persistence response increases azithromycin treatment failure in a murine model of infection.

Authors:  R Phillips-Campbell; J Kintner; R V Schoborg
Journal:  Antimicrob Agents Chemother       Date:  2014       Impact factor: 5.191

9.  Potency of Solithromycin against Fast- and Slow-Growing Chlamydial Organisms.

Authors:  Leiqiong Gao; Yao Wang; Ziyu Hua; Enmei Liu; Li Shen
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

10.  A novel inhibitor of Chlamydophila pneumoniae protein kinase D (PknD) inhibits phosphorylation of CdsD and suppresses bacterial replication.

Authors:  Dustin L Johnson; Chris B Stone; David C Bulir; Brian K Coombes; James B Mahony
Journal:  BMC Microbiol       Date:  2009-10-14       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.